Gastroenterology
Volume 136, Issue 5 , Pages 1639-1650 , May 2009

Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis

  • Marlene Dominguez

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBER de Enfermedades Hepáticas y Digestivas, Barcelona, Catalonia, Spain
    • ,
  • Rosa Miquel

      Affiliations

    • Pathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBER de Enfermedades Hepáticas y Digestivas, Barcelona, Catalonia, Spain
    • ,
  • Jordi Colmenero

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBER de Enfermedades Hepáticas y Digestivas, Barcelona, Catalonia, Spain
    • ,
  • Montserrat Moreno

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBER de Enfermedades Hepáticas y Digestivas, Barcelona, Catalonia, Spain
    • ,
  • Joan–Carles García–Pagán

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBER de Enfermedades Hepáticas y Digestivas, Barcelona, Catalonia, Spain
    • ,
  • Jaime Bosch

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBER de Enfermedades Hepáticas y Digestivas, Barcelona, Catalonia, Spain
    • ,
  • Vicente Arroyo

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBER de Enfermedades Hepáticas y Digestivas, Barcelona, Catalonia, Spain
    • ,
  • Pere Ginès

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBER de Enfermedades Hepáticas y Digestivas, Barcelona, Catalonia, Spain
    • ,
  • Juan Caballería

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBER de Enfermedades Hepáticas y Digestivas, Barcelona, Catalonia, Spain
    • ,
  • Ramón Bataller

      Affiliations

    • Liver Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, CIBER de Enfermedades Hepáticas y Digestivas, Barcelona, Catalonia, Spain
    • Corresponding Author InformationReprint requests Address requests for reprints to: Ramón Bataller, MD, Liver Unit, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. fax: 34 934515522

Received 5 August 2008 ,Accepted 29 January 2009.

References 

  1. Pares A, Caballeria J, Bruguera M, et al. Histological course of alcoholic hepatitis (Influence of abstinence, sex and extent of hepatic damage). J Hepatol. 1986;2:33–42
  2. Purohit V, Russo D. Cellular and molecular mechanisms of alcoholic hepatitis: introduction and summary of the symposium. Alcohol. 2002;27:3–6
  3. Walsh K, Alexander G. Alcoholic liver disease. Postgrad Med J. 2000;76:280–286
  4. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology. 1978;75:193–199
  5. Dominguez M, Rincon D, Abraldes JG, et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol. 2008;103:2747–2756
  6. Ramaiah SK, Jaeschke H. Role of neutrophils in the pathogenesis of acute inflammatory liver injury. Toxicol Pathol. 2007;35:757–766
  7. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343:1467–1476
  8. Taieb J, Mathurin P, Elbim C, et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol. 2000;32:579–586
  9. Taieb J, Chollet-Martin S, Cohard M, et al. The role of interleukin-10 in severe acute alcoholic hepatitis. Clin Biochem. 2001;34:237–238
  10. Naveau S, Chollet-Martin S, Dharancy S, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39:1390–1397
  11. Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology. 2008;135:1953–1960
  12. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol. 2000;68:1–8
  13. Bizzarri C, Beccari AR, Bertini R, et al. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacol Ther. 2006;112:139–149
  14. Graves DT, Jiang Y. Chemokines, a family of chemotactic cytokines. Crit Rev Oral Biol Med. 1995;6:109–118
  15. Maltby J, Wright S, Bird G, et al. Chemokine levels in human liver homogenates: associations between GRO alpha and histopathological evidence of alcoholic hepatitis. Hepatology. 1996;24:1156–1160
  16. Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci. 2002;7:d1899–d1914
  17. Bautista AP. Neutrophilic infiltration in alcoholic hepatitis. Alcohol. 2002;27:17–21
  18. Bird G. Interleukin-8 in alcoholic liver disease. Acta Gastroenterol Belg. 1994;57:255–259
  19. Ciecko-Michalska I, Szczepanek M, Cibor D, et al. Serum cytokine concentration as prognostic factor in patients with alcoholic liver disease. Przegl Lek. 2006;63:249–252
  20. Hill DB, Marsano LS, McClain CJ. Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology. 1993;18:576–580
  21. Huang YS, Chan CY, Wu JC, et al. Serum levels of interleukin-8 in alcoholic liver disease: relationship with disease stage, biochemical parameters and survival. J Hepatol. 1996;24:377–384
  22. Huang YS, Wu JC, Chang FY, et al. Interleukin-8 and alcoholic liver disease. Zhonghua Yi Xue Za Zhi (Taipei). 1999;62:395–401
  23. Ishii K, Furudera S, Kumashiro R, et al. Role of serum interleukin-8 and intercellular adhesion molecule-1 in the severity of alcoholic hepatitis. Alcohol Alcohol Suppl. 1994;29:81–85
  24. Colmenero J, Bataller R, Sancho-Bru P, et al. Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology. 2007;132:687–697
  25. Afford SC, Fisher NC, Neil DA, et al. Distinct patterns of chemokine expression are associated with leukocyte recruitment in alcoholic hepatitis and alcoholic cirrhosis. J Pathol. 1998;186:82–89
  26. Hasin D. Classification of alcohol use disorders. Alcohol Res Health. 2003;27:5–17
  27. Bosch J, Garcia-Pagan JC, Berzigotti A, et al. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis. 2006;26:348–362
  28. Asselah T, Bieche I, Laurendeau I, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology. 2005;129:2064–2075
  29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25:402–408
  30. Iimuro Y, Gallucci RM, Luster MI, et al. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology. 1997;26:1530–1537
  31. Ponnappa BC, Israel Y, Aini M, et al. Inhibition of tumor necrosis factor alpha secretion and prevention of liver injury in ethanol-fed rats by antisense oligonucleotides. Biochem Pharmacol. 2005;69:569–577
  32. Saito H, Ishii H. Recent understanding of immunological aspects in alcoholic hepatitis. Hepatol Res. 2004;30:193–198
  33. Siegmund S, Spanagel R, Singer MV. Role of the brain-gut axis in alcohol-related gastrointestinal diseases—what can we learn from new animal models?. J Physiol Pharmacol. 2003;54(Suppl 4):191–207
  34. Rincon D, Lo IO, Ripoll C, et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther. 2007;25:841–848
  35. Spahr L, Rubbia-Brandt L, Frossard JL, et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol. 2002;37:448–455
  36. Gonzalez-Quintela A, Campos J, Gude F, et al. Serum concentrations of interleukin-8 in relation to different levels of alcohol consumption. Cytokine. 2007;38:54–60
  37. Swiatkowska-Stodulska R, Bakowska A, Drobinska-Jurowiecka A. Interleukin-8 in the blood serum of patients with alcoholic liver disease. Med Sci Monit. 2006;12:CR215–CR220
  38. Jaeschke H. Neutrophil-mediated tissue injury in alcoholic hepatitis. Alcohol. 2002;27:23–27
  39. Bautista AP. Chronic alcohol intoxication primes Kupffer cells and endothelial cells for enhanced CC-chemokine production and concomitantly suppresses phagocytosis and chemotaxis. Front Biosci. 2002;7:a117–a125
  40. Tsukamoto H. Cytokine regulation of hepatic stellate cells in liver fibrosis. Alcohol Clin Exp Res. 1999;23:911–916
  41. Bertolani C, Sancho-Bru P, Failli P, et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol. 2006;169:2042–2053
  42. McClain CJ, Barve S, Deaciuc I, et al. Cytokines in alcoholic liver disease. Semin Liver Dis. 1999;19:205–219
  43. Jaruga B, Hong F, Kim WH, et al. IFN-gamma/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1044–G1052
  44. Cavalieri B, Mosca M, Ramadori P, et al. Neutrophil recruitment in the reperfused-injured rat liver was effectively attenuated by repertaxin, a novel allosteric noncompetitive inhibitor of CXCL8 receptors: a therapeutic approach for the treatment of post-ischemic hepatic syndromes. Int J Immunopathol Pharmacol. 2005;18:475–486

 Conflicts of interest The authors disclose no conflicts.

 Funding This work is supported by grants from the Ministerio de Ciencia y Tecnología, Dirección General de Investigación (SAF 2005-06245), from the Instituto de Salud Carlos III (FIS 05/050567, FIS PI 060085, and PI 080237), and from the European Community (V2006-CE036644). Dr Dominguez received a grant from the Institut d'Investigacions Biomèdiques August Pi i Sunyer and from the Fundación Banco Bilbao Vizcaya Argentaria. Dr Moreno received a grant from the Institut d'Investigacions Biomèdiques August Pi i Sunyer.

PII: S0016-5085(09)00160-7

doi: 10.1053/j.gastro.2009.01.056

Gastroenterology
Volume 136, Issue 5 , Pages 1639-1650 , May 2009

Article Tools

* Image Usage & Resolution